

# Hongmei Cui

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6848885/publications.pdf>

Version: 2024-02-01

7  
papers

127  
citations

1478280

6  
h-index

1719901

7  
g-index

7  
all docs

7  
docs citations

7  
times ranked

138  
citing authors

#	ARTICLE	IF	CITATIONS
1	Inhibition of USP14 enhances anti-tumor effect in vemurafenib-resistant melanoma by regulation of Skp2. <i>Cell Biology and Toxicology</i> , 2023, 39, 2381-2399.	2.4	8
2	Insights into the critical role of the PXR in preventing carcinogenesis and chemotherapeutic drug resistance. <i>International Journal of Biological Sciences</i> , 2022, 18, 742-759.	2.6	12
3	Nuclear Receptor PXR Confers Irradiation Resistance by Promoting DNA Damage Response Through Stabilization of ATF3. <i>Frontiers in Oncology</i> , 2022, 12, 837980.	1.3	7
4	The Tubulin Inhibitor VERU-111 in Combination With Vemurafenib Provides an Effective Treatment of Vemurafenib-Resistant A375 Melanoma. <i>Frontiers in Pharmacology</i> , 2021, 12, 637098.	1.6	6
5	Emerging Roles of SKP2 in Cancer Drug Resistance. <i>Cells</i> , 2021, 10, 1147.	1.8	19
6	Recent Advances in Elucidating Paclitaxel Resistance Mechanisms in Non-small Cell Lung Cancer and Strategies to Overcome Drug Resistance. <i>Current Medicinal Chemistry</i> , 2020, 27, 6573-6595.	1.2	35
7	The stress-responsive gene ATF3 regulates the histone acetyltransferase Tip60. <i>Nature Communications</i> , 2015, 6, 6752.	5.8	40